ω-3多不饱和脂肪酸补充剂对人体肠道微生物群影响的随机试验
该随机、开放标签、交叉试验纳入22名中年健康志愿者,比较两种配方(软胶囊和Smartfish饮品)的4克混合二十碳五烯酸/二十二碳六烯酸补充8周对粪便微生物群的影响。结果显示两种配方均诱导双歧杆菌属、罗斯氏菌属和乳杆菌属等几个属的丰度可逆性增加,且与给药方式无关;微生物群变化与红细胞ω-3多不饱和脂肪酸掺入或腹泻发生无关。
要点
- 两种ω-3多不饱和脂肪酸配方均诱导几个产短链脂肪酸细菌属的可逆性增加。
- 微生物群变化与红细胞ω-3多不饱和脂肪酸掺入无相关性。
- 补充ω-3多不饱和脂肪酸对α多样性、β多样性或门水平组成无显著影响。
核心结论
- ω-3多不饱和脂肪酸补充诱导几个产短链脂肪酸细菌的可逆性增加,与给药方式无关。
- 肠道微生物群与全身ω-3多不饱和脂肪酸暴露之间没有简单关系。
研究设计与样本
- 随机、开放标签、交叉试验,8周治疗期用4克混合二十碳五烯酸/二十二碳六烯酸两种配方(软胶囊和Smartfish饮品),间隔12周洗脱期。
- 纳入22名中年健康志愿者,在五个时间点收集粪便样本,通过16S核糖体RNA PCR和Illumina MiSeq测序分析微生物群。
- 通过液相色谱串联质谱法进行红细胞脂肪酸分析。
主要发现
- 两种ω-3多不饱和脂肪酸配方诱导红细胞脂肪酸含量相似变化,但饮品组与胶囊组相比,ω-6多不饱和脂肪酸花生四烯酸下降幅度更大且更持久(p=0.02)。
- 与ω-3多不饱和脂肪酸补充相关的α多样性、β多样性或门水平组成无显著变化。
- 观察到双歧杆菌属、罗斯氏菌属和乳杆菌属等几个属的丰度可逆性增加,见于一种或两种ω-3多不饱和脂肪酸干预。
- 微生物群变化与红细胞ω-3多不饱和脂肪酸掺入或ω-3多不饱和脂肪酸诱导的腹泻发生无相关性。
- 无治疗顺序效应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Omega-3 polyunsaturated fatty acids (PUFAs) have anticolorectal cancer (CRC) activity. The intestinal microbiota has been implicated in colorectal carcinogenesis. Dietary omega-3 PUFAs alter the mouse intestinal microbiome compatible with antineoplastic activity. Therefore, we investigated the effect of omega-3 PUFA supplements on the faecal microbiome in middle-aged, healthy volunteers (n=22). DESIGN: A randomised, open-label, cross-over trial of 8 weeks' treatment with 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in two formulations (soft-gel capsules and Smartfish drinks), separated by a 12-week 'washout' period. Faecal samples were collected at five time-points for microbiome analysis by 16S ribosomal RNA PCR and Illumina MiSeq sequencing. Red blood cell (RBC) fatty acid analysis was performed by liquid chromatography tandem mass spectrometry. RESULTS: Both omega-3 PUFA formulations induced similar changes in RBC fatty acid content, except that drinks were associated with a larger, and more prolonged, decrease in omega-6 PUFA arachidonic acid than the capsule intervention (p=0.02). There were no significant changes in α or β diversity, or phyla composition, associated with omega-3 PUFA supplementation. However, a reversible increased abundance of several genera, including Bifidobacterium, Roseburia and Lactobacillus was observed with one or both omega-3 PUFA interventions. Microbiome changes did not correlate with RBC omega-3 PUFA incorporation or development of omega-3 PUFA-induced diarrhoea. There were no treatment order effects. CONCLUSION: Omega-3 PUFA supplementation induces a reversible increase in several short-chain fatty acid-producing bacteria, independently of the method of administration. There is no simple relationship between the intestinal microbiome and systemic omega-3 PUFA exposure. TRIAL REGISTRATION NUMBER: ISRCTN18662143.
引用
- Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 2017. PMID: 28951525. doi:10.1136/gutjnl-2017-314968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。